| Recruiting | PALACE: Cemiplimab Trial According to ctDNA Levels NCT06917573 | Fundación GECP | Phase 2 |
| Recruiting | PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC NCT06102057 | TheraOp | Phase 2 |
| Recruiting | The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients NCT06082492 | Radboud University Medical Center | N/A |
| Not Yet Recruiting | Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectabl NCT05891080 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 |
| Terminated | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancr NCT05631574 | Biomea Fusion Inc. | Phase 1 |
| Withdrawn | Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer NCT05488626 | Varian, a Siemens Healthineers Company | N/A |
| Recruiting | A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresecta NCT05361174 | Iovance Biotherapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus NCT05468242 | Sun Yat-sen University | Phase 2 |
| Unknown | Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC NCT05157542 | Juan LI, MD | Phase 1 |
| Terminated | Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC NCT04441138 | Rush University Medical Center | Phase 2 |
| Unknown | A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC) NCT04325763 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 |
| Unknown | Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC NCT04304638 | Chinese Academy of Medical Sciences | — |
| Unknown | Treatment of Patients With Stage III Non-small Cell Lung Cancer in Russia" NCT05157503 | Autonomous Non-Profit Organization National Society of Onco-Pulmonologists | — |
| Unknown | A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer NCT04181372 | The First Affiliated Hospital of Guangzhou Medical University | Phase 2 |
| Active Not Recruiting | Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivoluma NCT04085250 | Sun Yat-sen University | Phase 2 |
| Terminated | Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically NCT03871153 | Greg Durm, MD | Phase 2 |
| Completed | Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung NCT03589547 | Brown University | Phase 2 |
| Unknown | Construction of CT Radiomics Model for Predicting the Efficacy of Immunotherapy in Patients With Stage III NSC NCT04984148 | Guangdong Provincial People's Hospital | — |
| Completed | Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC NCT03822351 | MedImmune LLC | Phase 2 |
| Recruiting | Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC NCT03742687 | Danish Lung Cancer Group | N/A |
| Completed | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer NCT03154190 | Stanford University | N/A |
| Unknown | Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That C NCT03048500 | Northwestern University | Phase 2 |
| Completed | Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 NCT03049618 | University of Southern California | Phase 2 |
| Completed | Omitting Clinical Target Volume of Unresectable Stage III Non-small-cell Lung Cancer. NCT05331833 | Jianguo Sun | — |
| Unknown | Image-Guided Functional Lung Avoidance Thoracic Radiotherapy for Lung Cancer: A Single-Blind Randomized Trial NCT03077854 | National Taiwan University Hospital | N/A |
| Unknown | MRI Optimization Study in Stage III NSCLC NCT02076282 | UMC Utrecht | — |
| Completed | Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Ch NCT01948141 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC NCT01733589 | Zhejiang Cancer Hospital | Phase 1 / Phase 2 |
| Terminated | Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)Radiotherapy NCT01577212 | Radboud University Medical Center | Phase 2 |
| Unknown | Radiotherapy Dose Complement in the Treatment of Hypoxic Lesions Patients With Stage III Non-small-cell Lung C NCT01576796 | Centre Henri Becquerel | Phase 2 |
| Withdrawn | Consolidation Chemotherapy/Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer ( NCT01336543 | Syed Jafri | Phase 2 |
| Completed | Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC) NCT01102231 | Intergroupe Francophone de Cancerologie Thoracique | Phase 2 |
| Unknown | Hypofractionated Intensity Modulated Chemoradiotherapy to Treat Locally Advanced Non-Small Cell Lung Cancer NCT00938418 | National University Hospital, Singapore | Phase 2 |
| Completed | Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC NCT01282437 | Maastricht Radiation Oncology | Phase 3 |
| Completed | Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer NCT00019006 | National Cancer Institute (NCI) | Phase 1 |